Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Anemia 55Neoplasms 27Leukemia 12Multiple Myeloma 11Lymphoma 9Neoplasms, Plasma Cell 8Lymphoma, Non-Hodgkin 7Leukemia, Lymphocytic, Chronic, B-Cell 7Breast Neoplasms 7Lymphoma, Follicular 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Precancerous Conditions 5Lymphoma, Mantle-Cell 5Lymphoma, Large-Cell, Immunoblastic 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, B-Cell, Marginal Zone 5Hodgkin Disease 5Waldenstrom Macroglobulinemia 4Myelodysplastic Syndromes 4Lymphoproliferative Disorders 4Fatigue 4Sezary Syndrome 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Myeloproliferative Disorders 3Mycosis Fungoides 3Monoclonal Gammopathy of Undetermined Significance 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Large-Cell, Anaplastic 3Lung Neoplasms 3Leukemia, Prolymphocytic 3

Interventions

Acupuncture Therapy 10Exercise 7Cryotherapy 6Paclitaxel 5Glutamine 5Surveys and Questionnaires 3Duloxetine Hydrochloride 3Dexamethasone 3Bortezomib 3Acetylcysteine 3pembrolizumab 2enfortumab vedotin 2Thioctic Acid 2Tablets 2Sodium Chloride 2Saline Solution 2Physical Therapy Modalities 2Low-Level Light Therapy 2Lenalidomide 2Fish Oils 2Fatty Acids, Omega-3 2ziconotide 1sagopilone 1nicotinamide-beta-riboside 1nabilone 1glutamic acid diethyl ester 1eribulin 1allantoicase 1Yoga 1XELOX 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Peripheral Nervous System Diseases × Epoetin Alfa × Clear all
NCT00267007 2014-06-04

A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2 Terminated
32 enrolled 9 charts

Neoplasms, Peripheral Nervous System Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡